Jason M Fritzler1, Guan Zhu. 1. Department of Biology, College of Sciences and Mathematics, Stephen F. Austin State University, Nacogdoches, TX 75962, USA.
Abstract
BACKGROUND: Cryptosporidium parvum causes an opportunistic infection in AIDS patients, and no effective treatments are yet available. This parasite possesses a single fatty acyl-CoA binding protein (CpACBP1) that is localized to the unique parasitophorous vacuole membrane (PVM). The major goal of this study was to identify inhibitors from known drugs against CpACBP1 as potential new anti-Cryptosporidium agents. METHODS: A fluorescence assay was developed to detect CpACBP1 activity and to identify inhibitors by screening known drugs. Efficacies of top CpACBP1 inhibitors against Cryptosporidium growth in vitro were evaluated using a quantitative RT-PCR assay. RESULTS: Nitrobenzoxadiazole-labelled palmitoyl-CoA significantly increased the fluorescent emission upon binding to CpACBP1 (excitation/emission 460/538 nm), which was quantified to determine the CpACBP1 activity and binding kinetics. The fluorescence assay was used to screen a collection of 1040 compounds containing mostly known drugs, and identified the 28 most active compounds that could inhibit CpACBP1 activity with sub-micromolar IC(50) values. Among them, four compounds displayed efficacies against parasite growth in vitro with low micromolar IC(50) values. The effective compounds were broxyquinoline (IC(50) 64.9 μM), cloxyquin (IC(50) 25.1 μM), cloxacillin sodium (IC(50) 36.2 μM) and sodium dehydrocholate (IC(50) 53.2 μM). CONCLUSIONS: The fluorescence ACBP assay can be effectively used to screen known drugs or other compound libraries. Novel anti-Cryptosporidium activity was observed in four top CpACBP1 inhibitors, which may be further investigated for their potential to be repurposed to treat cryptosporidiosis and to serve as leads for drug development.
BACKGROUND:Cryptosporidium parvum causes an opportunistic infection in AIDSpatients, and no effective treatments are yet available. This parasite possesses a single fatty acyl-CoA binding protein (CpACBP1) that is localized to the unique parasitophorous vacuole membrane (PVM). The major goal of this study was to identify inhibitors from known drugs against CpACBP1 as potential new anti-Cryptosporidium agents. METHODS: A fluorescence assay was developed to detect CpACBP1 activity and to identify inhibitors by screening known drugs. Efficacies of top CpACBP1 inhibitors against Cryptosporidium growth in vitro were evaluated using a quantitative RT-PCR assay. RESULTS:Nitrobenzoxadiazole-labelled palmitoyl-CoA significantly increased the fluorescent emission upon binding to CpACBP1 (excitation/emission 460/538 nm), which was quantified to determine the CpACBP1 activity and binding kinetics. The fluorescence assay was used to screen a collection of 1040 compounds containing mostly known drugs, and identified the 28 most active compounds that could inhibit CpACBP1 activity with sub-micromolar IC(50) values. Among them, four compounds displayed efficacies against parasite growth in vitro with low micromolar IC(50) values. The effective compounds were broxyquinoline (IC(50) 64.9 μM), cloxyquin (IC(50) 25.1 μM), cloxacillin sodium (IC(50) 36.2 μM) and sodium dehydrocholate (IC(50) 53.2 μM). CONCLUSIONS: The fluorescence ACBP assay can be effectively used to screen known drugs or other compound libraries. Novel anti-Cryptosporidium activity was observed in four top CpACBP1 inhibitors, which may be further investigated for their potential to be repurposed to treat cryptosporidiosis and to serve as leads for drug development.
Authors: S Pukrittayakamee; S Prakongpan; S Wanwimolruk; R Clemens; S Looareesuwan; N J White Journal: Antimicrob Agents Chemother Date: 2003-05 Impact factor: 5.191
Authors: Suresh Kumar Gorla; Nina N McNair; Guangyi Yang; Song Gao; Ming Hu; Venkatakrishna R Jala; Bodduluri Haribabu; Boris Striepen; Gregory D Cuny; Jan R Mead; Lizbeth Hedstrom Journal: Antimicrob Agents Chemother Date: 2013-12-23 Impact factor: 5.191
Authors: Eric Soupene; Joseph Kao; Daniel H Cheng; Derek Wang; Alexander L Greninger; Giselle M Knudsen; Joseph L DeRisi; Frans A Kuypers Journal: J Lipid Res Date: 2015-11-30 Impact factor: 5.922
Authors: William Checkley; A Clinton White; Devan Jaganath; Michael J Arrowood; Rachel M Chalmers; Xian-Ming Chen; Ronald Fayer; Jeffrey K Griffiths; Richard L Guerrant; Lizbeth Hedstrom; Christopher D Huston; Karen L Kotloff; Gagandeep Kang; Jan R Mead; Mark Miller; William A Petri; Jeffrey W Priest; David S Roos; Boris Striepen; R C Andrew Thompson; Honorine D Ward; Wesley A Van Voorhis; Lihua Xiao; Guan Zhu; Eric R Houpt Journal: Lancet Infect Dis Date: 2014-09-29 Impact factor: 25.071
Authors: Fengguang Guo; Haili Zhang; Jason M Fritzler; S Dean Rider; Lixin Xiang; Nina N McNair; Jan R Mead; Guan Zhu Journal: J Infect Dis Date: 2013-11-23 Impact factor: 5.226
Authors: Melissa S Love; Federico C Beasley; Rajiv S Jumani; Timothy M Wright; Arnab K Chatterjee; Christopher D Huston; Peter G Schultz; Case W McNamara Journal: PLoS Negl Trop Dis Date: 2017-02-03
Authors: Christopher D Huston; Thomas Spangenberg; Jeremy Burrows; Paul Willis; Timothy N C Wells; Wesley van Voorhis Journal: PLoS Negl Trop Dis Date: 2015-10-08